Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation.
Aged
Alleles
Antibodies, Monoclonal, Humanized
/ therapeutic use
Complement System Proteins
/ immunology
Female
Gene Deletion
Genes, X-Linked
Germany
Glycosylphosphatidylinositols
/ metabolism
Hemoglobinuria, Paroxysmal
/ immunology
Hemolysis
/ drug effects
Humans
Inflammasomes
/ immunology
Inflammation
/ immunology
Japan
Leukocytes
/ immunology
Male
Membrane Proteins
/ genetics
Middle Aged
Mutation
Point Mutation
THP-1 Cells
Complement
Glycobiology
Hematology
Inflammation
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
02 12 2019
02 12 2019
Historique:
received:
19
07
2018
accepted:
16
08
2019
pubmed:
21
8
2019
medline:
23
6
2020
entrez:
21
8
2019
Statut:
ppublish
Résumé
Patients with paroxysmal nocturnal hemoglobinuria (PNH) have a clonal population of blood cells deficient in glycosylphosphatidylinositol-anchored (GPI-anchored) proteins, resulting from a mutation in the X-linked gene PIGA. Here we report on a set of patients in whom PNH results instead from biallelic mutation of PIGT on chromosome 20. These PIGT-PNH patients have clinically typical PNH, but they have in addition prominent autoinflammatory features, including recurrent attacks of aseptic meningitis. In all these patients we find a germ-line point mutation in one PIGT allele, whereas the other PIGT allele is removed by somatic deletion of a 20q region comprising maternally imprinted genes implicated in myeloproliferative syndromes. Unlike in PIGA-PNH cells, GPI is synthesized in PIGT-PNH cells and, since its attachment to proteins is blocked, free GPI is expressed on the cell surface. From studies of patients' leukocytes and of PIGT-KO THP-1 cells we show that, through increased IL-1β secretion, activation of the lectin pathway of complement and generation of C5b-9 complexes, free GPI is the agent of autoinflammation. Eculizumab treatment abrogates not only intravascular hemolysis, but also autoinflammation. Thus, PIGT-PNH differs from PIGA-PNH both in the mechanism of clonal expansion and in clinical manifestations.
Identifiants
pubmed: 31430258
pii: 123501
doi: 10.1172/JCI123501
pmc: PMC6877298
doi:
pii:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Glycosylphosphatidylinositols
0
Inflammasomes
0
Membrane Proteins
0
phosphatidylinositol glycan-class A protein
0
Complement System Proteins
9007-36-7
eculizumab
A3ULP0F556
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5123-5136Commentaires et corrections
Type : CommentIn
Références
J Biol Chem. 1997 Jun 20;272(25):15834-40
pubmed: 9188481
Mol Immunol. 2004 Jun;41(2-3):103-11
pubmed: 15159055
Blood. 2005 Dec 1;106(12):3699-709
pubmed: 16051736
Mol Biol Cell. 2003 May;14(5):1780-9
pubmed: 12802054
Neurogenetics. 2014 Aug;15(3):193-200
pubmed: 24906948
Immunol Rev. 2004 Apr;198:185-202
pubmed: 15199963
Br J Haematol. 2003 Oct;123(1):173-6
pubmed: 14510962
Blood. 2008 Feb 15;111(4):2132-41
pubmed: 18063752
Nat Commun. 2018 Jan 26;9(1):405
pubmed: 29374258
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Br J Haematol. 2013 Jul;162(1):62-73
pubmed: 23617322
Brain Dev. 2018 Jan;40(1):53-57
pubmed: 28728837
BMJ Case Rep. 2018 Sep 27;2018:null
pubmed: 30262533
Genes (Basel). 2016 Nov 29;7(12):
pubmed: 27916860
J Biol Chem. 2012 Feb 24;287(9):6318-25
pubmed: 22228761
Front Genet. 2018 May 08;9:153
pubmed: 29868109
FASEB J. 2017 Jun;31(6):2439-2445
pubmed: 28246166
J Med Genet. 2013 Aug;50(8):521-8
pubmed: 23636107
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7938-43
pubmed: 8755581
J Clin Invest. 2014 Oct;124(10):4529-38
pubmed: 25244093
Science. 1993 Feb 26;259(5099):1318-20
pubmed: 7680492
Oncogene. 2000 Aug 10;19(34):3902-13
pubmed: 10952764
J Immunol. 2014 Mar 15;192(6):2837-45
pubmed: 24554772
Science. 1995 Jul 7;269(5220):89-92
pubmed: 7541557
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
J Immunol. 2013 Aug 1;191(3):1006-10
pubmed: 23817414
J Biol Chem. 1998 Jan 23;273(4):2355-60
pubmed: 9442081
Nat Clin Pract Rheumatol. 2008 Sep;4(9):481-9
pubmed: 18665151
J Biol Chem. 1996 Feb 2;271(5):2448-54
pubmed: 8576206
Proc Natl Acad Sci U S A. 2004 May 11;101(19):7341-6
pubmed: 15123827
N Engl J Med. 2006 Sep 21;355(12):1233-43
pubmed: 16990386
EMBO J. 2002 Oct 1;21(19):5047-56
pubmed: 12356721
EMBO J. 2001 Aug 1;20(15):4088-98
pubmed: 11483512
Cell. 1997 Jan 10;88(1):1-4
pubmed: 9019395
J Exp Med. 2001 Feb 5;193(3):393-7
pubmed: 11157059
Cell. 1993 May 21;73(4):703-11
pubmed: 8500164
Semin Hematol. 1989 Jul;26(3):201-7
pubmed: 2675316
FEBS Lett. 2002 Feb 13;512(1-3):249-54
pubmed: 11852090
J Biol Chem. 2002 Dec 20;277(51):49403-7
pubmed: 12384495
Mol Genet Metab. 2015 Jun-Jul;115(2-3):128-140
pubmed: 25943031
Blood. 2013 Aug 15;122(7):1312-5
pubmed: 23733340
J Biol Chem. 2019 Mar 29;294(13):5038-5049
pubmed: 30728244
Immunity. 2017 Jun 20;46(6):943-956
pubmed: 28636961
Science. 2016 Jun 17;352(6292):aad1210
pubmed: 27313051
Br J Haematol. 2001 Nov;115(2):360-8
pubmed: 11703336
Eur J Immunol. 2014 Dec;44(12):3669-79
pubmed: 25229885
Eur J Hum Genet. 2017 Jun;25(6):669-679
pubmed: 28327575
J Clin Invest. 2013 May;123(5):2169-82
pubmed: 23543057
Immunology. 1994 May;82(1):34-41
pubmed: 7519172
Parasitology. 1994 Feb;108 ( Pt 2):139-45
pubmed: 7512710
Nat Rev Dis Primers. 2017 May 18;3:17028
pubmed: 28516949
Br J Haematol. 2018 Sep;182(6):758-776
pubmed: 29974931
Blood. 1992 Mar 15;79(6):1385-92
pubmed: 1547338
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315
Genet Med. 2019 Oct;21(10):2216-2223
pubmed: 30976099
Acta Neuropathol. 1995;89(3):239-47
pubmed: 7754744
Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(4):130-43
pubmed: 24727937
Am J Clin Pathol. 2000 Sep;114(3):459-66
pubmed: 10989647
Blood. 2006 Dec 15;108(13):4232-6
pubmed: 16940417